Filing Flows › Treace Medical Concepts (TMCI) › Q3 2026 › vs Q2 2026
Treace Medical Concepts (TMCI) Q3 2026 vs Q2 2026 (quarter over quarter)
Treace Medical Concepts's revenue rose $2.9M (+6%) from $45.4M in Q2 2026 to $48.3M in Q3 2026.
Treace Medical Concepts, Q3 2026: revenue $48.3M (-4% year over year), operating margin -23.9%, net loss $12.6M, operating cash flow −$3.3M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $48.3M | $45.4M | $2.9M | +6% |
| Net loss | $12.6M | $15.9M | −$3.3M | -21% |
| Costs & expenses | $60.8M | $61.2M | −$430K | -0.7% |
| Operating costs | $59.8M | $60.3M | −$549K | -0.9% |
| Interest & other, net | $1.0M | $915K | $119K | +13% |
| Cost of revenue | $9.9M | $9.8M | $134K | +1% |
| Research & development | $4.5M | $4.4M | $116K | +3% |
| Sales & marketing | $29.7M | $30.9M | −$1.2M | -4% |
| General & admin | $15.7M | $15.2M | $433K | +3% |
| Operating cash sources | $12.6M | $15.9M | −$3.3M | -21% |
| Depreciation & amortization | $2.0M | $1.9M | $144K | +8% |
| Share-based compensation | $6.9M | $6.5M | $468K | +7% |
| Working capital & other | $348K | $2.8M | −$2.5M | -88% |
| Cash used in operations | $3.3M | $4.7M | −$1.4M | -31% |
| Net loss absorbed | $12.6M | $15.9M | −$3.3M | -21% |
Questions
How much did Treace Medical Concepts's revenue grow quarter over quarter in Q3 2026?
Treace Medical Concepts's revenue rose $2.9M (+6%) from $45.4M in Q2 2026 to $48.3M in Q3 2026.